Table 4 Recurrent Wilms’ tumor: clinical evidence and studies reports
Study (year) | Group | Patients | Chemotherapy | ASCT | EFS (%) | OS (%) | Ref. |
|---|---|---|---|---|---|---|---|
Abu Gosh et al. (2002) | CCG | 11 | ICE | No (2) | 3-year (63.6) | 63 | [21] |
Campbell et al. (2004) | Chicago | 13 | 7/13 cyclophosphamide–etoposide–carboplatin | No (1 or 2) | 4-year (60) | 73 | [22] |
Malogolowkin et al. (2007) | NWTS-5 | 60 | Cyclophosphamide–etoposide carboplatin–etoposide | No | 4-year (42.3) | 48 | [23] |
Sprea co et al. (2008) | AIEOP | 20 | ICE | MEC (8/15) | 3-year, 56 | 55 | [24] |
Hale et al. (2008) | UK CCLG | 45 | Cyclophosphamide–etoposide carboplatin–etoposide | Melphalan | 66 | [25] |